Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology

By Dominic ChoppingNovo Nordisk agreed to pay up to $1.3 billion to license and develop Swedish pharmaceutical company Nanexa's drug delivery technology in a deal that could cut the frequency that patients need to inject its obesity and diabetes drugs.The deal covers Nanexa's PharmaShell technology…